Shreeram Aradhye, Novartis CMO and president of global drug development
October 24, 2022 07:23 AM EDT
R&D

No­var­tis takes an­oth­er stride to­ward Alex­ion's turf with PhI­II PNH win

Amber Tong

Look­ing to break in­to a rare dis­ease field that As­traZeneca sub­sidiary Alex­ion has dom­i­nat­ed for years, No­var­tis says its oral drug best­ed an­ti-C5 ther­a­pies in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times